Big pharma interest remains, but the mood is fast turning gloomy.
ApexOnco Front Page
Recent articles
The Rosetta Breast-01 phase 3 trial will only evaluate patients with low PD-L1 expression.
The micro cap promises data this year, but its peer Kineta winds down a VISTA trial.
First-in-human clinical trial listings include AZD0754, Astra’s internally developed Car-T therapy.
Data on the group’s lead project, the PD-1 x CTLA-4 bispecific vudalimab, are far from emphatic.
Early activity of JANX007 in prostate cancer sees Janux stock gain 190%.
Not long after starting phase 1, RMC-6236 could be in pivotal trials this year.
An “optimised formulation” of bezuclastinib looks promising, but the safety question remains open.